The role of metabolic disorders in the pathophysiology of AD is shown by the consistent correlations of serum-based liver function markers with cognitive performance and amyloid β (Aβ), tau protein, and other AD neurodegeneration biomarkers (Nho et al., 2019). Here, MAPT is linked to Alzheimer disease.